|
IMMUNÉRIEUR CORPORATION (IMRX) VALUATION DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Immuneering Corporation (IMRX) Bundle
Optimisez votre temps et augmentez la précision avec notre calculatrice DCF (IMRX)! En utilisant les données réelles des sociétés d'immunination et les hypothèses réglables, cet outil vous permet de prévoir, analyser et valoriser (IMRX) comme un investisseur chevronné.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.3 | 2.1 | .3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -10.02 | -84.76 | -100 | 0 | -48.69 | -48.69 | -48.69 | -48.69 | -48.69 |
| EBITDA | -17.0 | -33.7 | -51.5 | -58.1 | -64,071.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -735.58 | -1619.46 | -16238.3 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .1 | .2 | .8 | .4 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 3.43 | 7.65 | 251.39 | 100 | 100 | 62.22 | 62.22 | 62.22 | 62.22 | 62.22 |
| EBIT | -17.1 | -33.8 | -52.3 | -58.4 | -64,071.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -739.01 | -1627.11 | -16489.69 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 37.1 | 149.2 | 105.5 | 85.7 | 36,144.7 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .5 | .2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 21.64 | 11.83 | 3.92 | 100 | 100 | 47.48 | 47.48 | 47.48 | 47.48 | 47.48 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0.000315505187 | 100 | 100 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | 1.5 | 1.4 | 3.2 | 2.1 | 2.0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 64.05 | 67.04 | 995.28 | 100 | 100 | 86.22 | 86.22 | 86.22 | 86.22 | 86.22 |
| Capital Expenditure | -.1 | -.1 | -.7 | -.3 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -2.31 | -2.92 | -234.26 | 100 | 100 | -21.05 | -21.05 | -21.05 | -21.05 | -21.05 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -17.1 | -33.5 | -51.0 | -58.4 | -64,071.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -16.1 | -33.3 | -48.9 | -59.4 | -64,071.6 | -2.0 | .0 | .0 | .0 | .0 |
| WACC, % | 4.16 | 4.12 | 4.06 | 4.16 | 4.16 | 4.13 | 4.13 | 4.13 | 4.13 | 4.13 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -31,982 | |||||||||
| Equity Value | 31,980 | |||||||||
| Diluted Shares Outstanding, MM | 30 | |||||||||
| Equity Value Per Share | 1,066.65 |
What You Will Get
- Comprehensive Financial Model: Leverage Immuneering’s actual data for accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue growth, margins, WACC, and other essential drivers.
- Real-Time Calculations: Automatic updates provide immediate results as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Adaptable and Reusable: Designed for versatility, allowing for ongoing use in detailed forecasts.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Immuneering Corporation (IMRX).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to IMRX.
- Customizable Forecast Assumptions: Update growth projections, capital expenditures, and discount rates as needed.
- Incorporated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Immuneering Corporation (IMRX).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Immuneering Corporation (IMRX) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Immuneering Corporation’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Immuneering Corporation (IMRX)?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for IMRX.
- Flexible Inputs: Modify yellow-highlighted cells to explore different investment scenarios.
- In-Depth Analysis: Automatically computes Immuneering's intrinsic value and Net Present Value.
- Rich Data Repository: Access historical and projected data for reliable analysis.
- Expert-Level Tool: Perfect for financial analysts, investors, and business advisors focused on IMRX.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions about investing in Immuneering Corporation (IMRX).
- Financial Analysts: Enhance your valuation processes with comprehensive financial models tailored for Immuneering Corporation (IMRX).
- Consultants: Provide clients with expert valuation analysis of Immuneering Corporation (IMRX) efficiently and effectively.
- Business Owners: Learn from the valuation strategies of biotech companies like Immuneering Corporation (IMRX) to refine your own business approach.
- Finance Students: Explore valuation methodologies using real data and case studies from Immuneering Corporation (IMRX).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Immuneering Corporation (IMRX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Immuneering Corporation (IMRX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.